Alkermes Plc at Stifel Healthcare Conference Transcript
All right. I think we're good to go. So I'm Nate Tower. I'm a member of the Stifel Research team on Paul Matteis' Biotech team. I'm happy to be joined by Blair Jackson, who's SVP of Corporate Planning for Alkermes. And I think we'll just have a 0.5 hour chat about the business. And I was hoping maybe we could just start it off. For those who are newer to the story, maybe you can give a brief overview of where the company has been, where it is today and where it's going?
Great. Well, thanks for having me today. I'm really happy to be talking about Alkermes. It's been an exciting year. 2019, there's been just a lot of changes fundamentally in the company.
We've really built a strong commercial organization on the back of a really interesting portfolio of CNS products. So we have a product called VIVITROL for the treatment of addiction, specifically opioid dependence and alcohol dependence. And it's a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |